Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • Switching to an integrase inhibitor to manage dyslipidemia appears attractive given the favorable metabolic profile of these agents in therapy-naive patients[Quercia 2015; Sierra-Madero 2010; Lennox 2010; Gallant 2017; Sax 2017]
  • Lipid parameters significantly improved in virologically suppressed patients who switched from a boosted PI to coformulated bictegravir/emtricitabine/tenofovir AF in Study 1878[Daar 2017]
  • Switching from a fully suppressive 3-drug regimen to the 2-drug regimen of dolutegravir/rilpivirine was associated with minimal effects on lipids and cardiovascular biomarkers[Llibre 2018]

Action required

Keywords: Cardiovascular Disease, Dyslipidemia, Switch Strategies, Treatment Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.